Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region

被引:14
|
作者
Jazieh, Abdul Rahman [1 ]
Jaafar, Iasan [2 ]
Jaloudi, Mohammed [2 ]
Mustafa, Rasha Saleh [3 ]
Rasul, Kakil [4 ]
Zekri, Jamal [5 ]
Bamefleh, Hanaa [1 ]
Gasmelseed, Ahmed [1 ]
机构
[1] King Saud bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Natl Guard Hlth Affairs, Dept Oncol, Riyadh 11426, Saudi Arabia
[2] Tawam Hosp, Dept Oncol, Al Ain 15258, U Arab Emirates
[3] King Fand Med City, Riyadh 11525, Saudi Arabia
[4] Al Amal Hosp, Dept Oncol, Doha 3050, Qatar
[5] King Faisal Specialist & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia
关键词
non-small-cell lung cancer; epidermal growth factor receptor; Gulf region;
D O I
10.3892/mco.2015.644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to determine the prevalence of epidermal growth factor receptor mutations (EGFRmut) in the Gulf region (GR) and its correlation with demographic and clinical characteristics. A multisite retrospective study was conducted, including institutions from Saudi Arabia, the United Arab Emirates and Qatar. All consecutive patients with non-small-cell lung cancer tested for EGFRmut were eligible. Data collected included demographic information, disease characteristics and EGFR test results. Data on 230 patients were obtained. The median age of the patients was 61 years (range, 26-87 years); 169 patients (69.83%) were male and 204 (88.7%) were Arab. The histological subtype was adenocarcinoma in 191 (83.4%) and squamous cell carcinoma in 21 cases (9.17%). Overall, EGFRmut were detected in 66 patients (28.7%), with a prevalence of 32.46% in adenocarcinoma. No squamous cell carcinomas were found to harbor EGFRmut. The univariate and multivariate analyses revealed that female gender, non-smoking status and adenocarcinoma subtype were significant predictors for EGFRmut. There was no difference between Arabs and non-Arabs. In conclusion, to the best of our knowledge, this is the first multisite study to report the prevalence of EGFRmut in the GR population, which was found to be higher compared with that in Western, but lower compared with that in Far Eastern populations. Studies evaluating the efficacy of targeted therapy in this population are underway.
引用
收藏
页码:1371 / 1374
页数:4
相关论文
共 50 条
  • [41] Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China
    Abdurahman, Ablajan
    Anwar, Jurat
    Turghun, Abdugheni
    Niyaz, Madiniyet
    Zhang, Liwei
    Awut, Idiris
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) : 847 - 850
  • [42] Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
    Van Der Steen, Nele
    Giovannetti, Elisa
    Carbone, Daniela
    Leonetti, Alessandro
    Rolfo, Christian D.
    Peters, Godefridus J.
    CANCER DRUG RESISTANCE, 2018, 1 (04) : 230 - 249
  • [43] MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor
    Liu, Lingxiang
    Shao, Xiaoyan
    Gao, Wen
    Zhang, Zhi
    Liu, Ping
    Wang, Rongsheng
    Huang, Puwen
    Yin, Yongmei
    Shu, Yongqian
    FEBS JOURNAL, 2012, 279 (20) : 3800 - 3812
  • [44] A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor
    Chen, Lun-Che
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, Ching-Yao
    RESPIROLOGY CASE REPORTS, 2019, 7 (05):
  • [45] Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
    Karlsen, Emma-Anne
    Kahler, Sam
    Tefay, Joan
    Joseph, Shannon R.
    Simpson, Fiona
    CELLS, 2021, 10 (05)
  • [46] Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
    Dong, Lijun
    Lei, Dan
    Zhang, Haijun
    ONCOTARGET, 2017, 8 (38) : 64600 - 64606
  • [47] Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: still to be established Reply
    Watzka, Stefan B.
    Koestler, Wolfgang J.
    Attems, Johannes
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 39 (03) : 428 - 428
  • [48] Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer
    Takenaka, Tomoyoshi
    Takenoyama, Mitsuhiro
    Yamaguchi, Masafumi
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Yoshida, Tsukihisa
    Shiraishi, Yoshimasa
    Morodomi, Yosuke
    Hirai, Fumihiko
    Taguchi, Kenichi
    Shimokawa, Mototsugu
    Seto, Takashi
    Ichinose, Yukito
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 47 (03) : 550 - 555
  • [49] Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer
    Gisondi, Paolo
    Geat, Davide
    Mattiucci, Alessandra
    Lombardo, Fiorella
    Santo, Antonio
    Girolomoni, Giampiero
    DERMATOLOGY, 2021, 237 (06) : 929 - 933
  • [50] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Liao, Bin-Chi
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Chen, Ya-Fang
    Chang, Chin-Hao
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1754 - 1761